Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01960816 · ClinicalTrials.gov registry record · NA

InFlux System for Nasal Breathing Improvement

A NA study of Nasal Airway Obstruction, sponsored by Aerin Medical.

Completed
Registry status
NA
Development phase
33
Enrollment target
2
Study locations

NCT01960816: Completed NA study of Nasal Airway Obstruction, sponsored by Aerin Medical.

NCT01960816 is a NA study of Nasal Airway Obstruction that has completed, run by Aerin Medical. The registered enrollment target is 33 participants, below the 181-participant average among 3 other Nasal Airway Obstruction trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01960816, a NA study of Nasal Airway Obstruction, has completed, sponsored by Aerin Medical.

COMPLETED
Registry status
NA
Development phase
33 participants
Enrollment target
2
Study locations

Study Summary

Pilot Study of the Aerin Medical Wand used for Improvement in Nasal Breathing

Primary Outcome

The study will be considered to have met its primary safety endpoint if no subject experiences an unanticipated serious adverse device effect (USADE defined as any serious adverse effect caused by, or associated with, the investigational device, that was not previously identified in nature, severity, or degree of incidence in the protocol)

Conditions Studied

Interventions

  • DEVICE Procedure: thermal coagulation of tissue in the nasal airway

Study Locations (2)

Massachusetts

  • St. Elizabeth's Medical Center - Boston

Mississippi

  • Bay Area ENT - Ocean Springs

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2013-09
Est. Completion 2016-04
Phase NA
Aerin Medical

14 total trials

What the finished NCT01960816 record still lists

NCT01960816 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 181-participant average among 3 other Nasal Airway Obstruction trials with a reported enrollment target (82% lower).

The record links to 1 condition, with Nasal Airway Obstruction appearing as the primary indexed condition, and to 1 intervention - of which Procedure: thermal coagulation of tissue in the nasal airway is the first listed.

NCT01960816 reports a single indexed study location in Massachusetts, Mississippi.

Frequently Asked Questions

What is clinical trial NCT01960816 about?

NCT01960816 is a clinical study titled "InFlux System for Nasal Breathing Improvement". Pilot Study of the Aerin Medical Wand used for Improvement in Nasal Breathing

What is the current status of trial NCT01960816?

This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2013-09. Estimated completion is 2016-04.

What conditions does trial NCT01960816 study?

This clinical trial studies the following conditions: Nasal Airway Obstruction.

What interventions are being tested in trial NCT01960816?

The interventions under investigation include: Procedure: thermal coagulation of tissue in the nasal airway (DEVICE).

Who is sponsoring clinical trial NCT01960816?

This trial is sponsored by Aerin Medical, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01960816 being conducted?

This trial has 2 study locations across Massachusetts, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nasal Airway Obstruction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02861898 · 33 participants · Phase 1

    Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

  • NCT04871607 · 33 participants · Phase 2

    Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

  • NCT05071937 · 33 participants · Phase 2

    ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

  • NCT05168618 · 33 participants · Phase 2

    Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01960816, the US trial registry maintained by the National Library of Medicine. NCT01960816 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.